Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2021.223 | Drug-Drug Interactions in Patients Treated with DAAs in Hong Kong | Prof. WONG Grace Lai Hung |
| 2023.265 | A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung Lai Hung Wong |
| 2022.653 | A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection | Prof. WONG Grace Lai Hung |
| 2023.151 | A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2023.268 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2023.344 | A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic HBV Infection and a Long-term Study to Evaluate the Safety, Tolerability, and Efficacy of BW-20507 with/without HEPLISAV-B® in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2022.324 | Chronic kidney disease progression in chronic hepatitis B patients on tenofovir alafenamide (TAF) versus entecavir |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.552 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2020.509 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection |
Prof Wong Grace Lai Hung 黃麗虹 |
| 2022.678 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in Participants with Chronic Hepatitis B Infection (STRIVE) | Prof. WONG Grace Lai Hung |
| 2021.091 | Comparative Risk of HCC in CHB Patients Receiving ETV or TDF-based Treatment: IPD Meta-Analysis Protocol |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.112 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2020.459 | Elimination of chronic hepatitis B in Hong Kong – to meet the WHO goals |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.601 | Real-World Data to Assess HCV Patients Treated with SOF/VEL without RBV |
Prof. Wong Grace Lai Hung 黃麗虹教授 |
| 2021.106 | Prospective evaluation of a fast-track treatment pathway for patients with chronic hepatitis B under primary care |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2009.169 | Prevalence of Advanced Fibrosis among Chronic Hepatitis C Patients in Hong Kong | Prof. WONG Grace Lai Hung |
| 2013.118 | Evaluation of clinical outcomes in patients with viral hepatitis B or C - a retrospective observational cohort study | Dr. WONG Grace Lai Hung |
| 2011.497 | Liver Cancer Treatment Collaboration Study | Dr. WONG Grace Lai Hung |
| 2025.372 | A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME) | Prof. WONG Grace Lai Hung |
| 2024.002 | A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2023.684 | A phase II clinical study to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B | Prof. WONG Grace Lai Hung |
| 2024.633 | Universal screening for hepatitis delta virus (HDV) in individuals living with HIV/HBV coinfection and HBV-related HCC | Prof. WONG Grace Lai Hung |
| 2025.847 | Multi-Modal Ultrasound Navigation and AI-Assisted Video Summarization for Diagnostic Enhancement | Prof. Wong Grace Lai Hung |
| 2024.361 | Overcoming Inequalities in Health to Eliminate Hepatitis – Real-World Evidence from a Territory-Wide Cohort |
Prof. WONG Grace Lai Hung Lai Hung Grace Wong |
| 2024.313 | A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod Alone and in Combinations in Subjects with Chronic Hepatitis B Infection | Prof. WONG Grace Lai Hung |
| 2025.296 | A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNα-2a, Nivolumab or Durvalumab in Subjects with Chronic Hepatitis B |
Prof. WONG Grace Lai Hung Grace Wong |
| 2024.057 | A Long-Term Follow-up Study for Subjects with Chronic Hepatitis B Previously Treated with Imdusiran (AB-729) | Prof. WONG Grace Lai Hung |
| 2024.058 | A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2025.802 | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants with Chronic Hepatitis B Virus Infection | Prof. WONG Grace Lai Hung |
| 2024.115 | Behavior, Aspirations and Treatment needs of people living with hepatitis B | Prof. WONG Grace Lai Hung |
| 2021.291 | The setting up of Geriatric Diabetes Programme in a regional hospital of Hong Kong | Dr. WONG Grace Hiu Yan |
| 2023.312 | An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B | Prof. WONG Grace |
| 2024.007 | Secular trend of chronic liver diseases - a retrospective observational cohort study | Prof. WONG Grace |
| 2025.597 | Construction of diagnostic and predictive models for cirrhosis patients with complications of liver disease | Prof. Wong Grace |
| 2024.460 | A Phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United) | Prof. WONG Grace |
| 2010.075 | Prediction of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Haemorrhage using Transient Hyperemic Response Test and Implications on Length of Hospitalization | Prof. Wong George Kwok-chu |
| 2007.436 | Co-Operative Study on Brain Injury Depolarisations (COSBID): (Traumatic and Ischaemic Injury to the Human Brain) | Dr. Wong George Kwok-chu |
| 2008.073 | Computed Tomography Antiography and Venography in Place of Catheter Angiography for Acute Spontaneous Non-Hypertensive Intracerebral Haemorrhage | Dr. Wong George Kwok-chu |
| 2008.076 | Disability in Young People and Adults One Year after Head Injury: Impact, Causes and Factors | Dr. Wong George Kwok-chu |
| 2022.666 | Mobile application development for impact assessment of patients after subarachnoid haemorrhage | Prof. WONG George Kwok Chu |
| 2023.035 | Machine-learning Method for Retinal Image Analysis to Detect Intracranial Aneurysms | Prof. WONG George Kwok Chu |
| 2021.390 | Impact of Ultra-Early Aneurysm Treatment on outcomes in Patients with Poor Neurological Status after Intracranial Aneurysm Rupture: a retrospective review |
Prof. WONG George Kwok Chu 黃國柱 |
| 2020.627 | Intracranial aneurysms in ischemic stroke patients: a retrospective review |
Prof. WONG George Kwok Chu 黃國柱 |
| 2022.291 | Adjunctive embolization for chronic subdural hematoma at high risk of recurrence: A Phase I RCT (Embo-Subdu I) | Prof. WONG George Kwok Chu |
| 2022.116 | Long term outcome of aneurysms treated with flow diverters: multi-center retrospective study | Prof. WONG George Kwok Chu |
| 2021.288 | Prospective Audit of Intracranial Aneurysm Stent Treatment | Prof. WONG George Kwok Chu |
| 2016.639 | Circulating-microRNA-based classifier of early brain injury after intracranial aneurysm rupture |
Prof. WONG George Kwok Chu 黃國柱 |
| 2017.345 | Prediction of treatment complications in patients with unruptured intracranial aneurysms undergoing preventive aneurysms treatment |
Prof. WONG George Kwok Chu 黃國柱 |
| 2015.401 | Investigation of neuroprotective effects of umbilical cord-derived mesenchymal stem cells against focal cerebral ischemia in rats |
Prof. WONG George Kwok Chu 黃國柱 |
| 2015.153 | Rivastigmine for cognitive impairment after aneurysmal subarachnoid hemorrhage: a randomized placebo-controlled clinical trial. | Prof. WONG George Kwok Chu |
Page 41 of 289.